---

---

symbols : AZN   

save search

---

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
Published: 2022-12-19 (Crawled : 13:20) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 0.81% | O: 0.99% H: 0.06% C: 0.06%
VERU | $1.305 -8.1% -8.81% 2.6M |

Health Technology

| -73.75% | O: 0.4% H: 0.4% C: -3.99%
FBIO | $1.765 -2.49% -2.55% 190K |

Health Technology

| 201.72% | O: 3.79% H: 3.82% C: -8.21%
ATXI | $0.1295 -3.79% -3.94% 320K |

Health Technology

| -89.52% | O: -0.81% H: 1.63% C: -6.5%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 0.9% | O: -0.07% H: 0.01% C: -0.62%
biotech

---

U.S. Gastroesophageal Reflux Disease Devices Market Report 2022-2027: Key Players AstraZeneca, Pfizer, Procter & Gamble & Others Driving 15.47% Growth
Published: 2022-07-29 (Crawled : 20:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| Email alert Add to watchlist
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| Email alert Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| Email alert Add to watchlist
disease report growth market

---

Global Glioblastoma Multiforme (GBM) Treatment Market Report 2023: Increasing Prevalence of Brain Disorders is Expected to Propel Growth
Published: 2023-05-17 (Crawled : 01:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| -9.92% | O: -1.32% H: 0.92% C: -1.34%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -8.22% | O: -0.51% H: 0.0% C: -1.05%
FUSN | $21.26 0.05% 0.05% 440K |

Health Technology

| 366.23% | O: -1.54% H: 1.34% C: -2.67%
DFFN 4 | $6.6 11.68% -34.32% 350K |

Health Technology

| 14.59% | O: -0.25% H: 0.0% C: -0.78%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| -8.94% | O: 0.07% H: 0.03% C: -0.84%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| 18.01% | O: -0.82% H: 0.03% C: -0.44%
propel report expected treatment global growth glioblastoma market

---

Proton Pump Inhibitors (PPIs) Market to grow by USD 807.89 million from 2023-2028 | North America to account for 36% of market growth - Technavio
Published: 2023-12-19 (Crawled : 07:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 6.41% | O: 3.81% H: 0.0% C: 0.0%
BHC | $8.69 1.05% 0.0% 2.9M |

Health Technology

| 17.91% | O: 1.22% H: 1.88% C: 0.94%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -4.44% | O: 0.45% H: 0.0% C: 0.0%
RDHL | $0.4519 7.39% 6.88% 330K |

Health Technology

| -63.11% | O: 0.82% H: 8.94% C: 7.32%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 3.94% | O: -0.5% H: 0.99% C: 0.43%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| -2.38% | O: 1.17% H: 0.67% C: -0.09%
america growth market

---

Human Papillomavirus Vaccine (HPV) Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR: Allied Market Research
Published: 2022-07-21 (Crawled : 13:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| -1.32% | O: 6.64% H: 0.0% C: -4.08%
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -11.58% | O: -2.38% H: 0.0% C: 0.0%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 4.84% | O: 0.15% H: 0.0% C: -3.5%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 12.04% | O: 0.09% H: 1.9% C: 1.89%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -14.1% | O: -1.18% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| -4.45% | O: 1.3% H: 0.38% C: -0.38%
XBIO | $4.14 7.32% 770 |

Health Technology

| -94.95% | O: 0.41% H: 7.44% C: -2.71%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -9.02% | O: -3.38% H: 0.0% C: 0.0%
INO 4 d | $9.68 -5.1% -5.37% 350K |

Health Technology

| 334.08% | O: 0.0% H: 1.35% C: -5.83%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 4.2% | O: -2.75% H: 2.31% C: 2.15%
research vaccine market

---

Cancer Gene Therapy Market To Reach a Valuation of USD 4047.8 Million by 2028 - Comprehensive Research Report by BrandEssence Market Research
Published: 2022-12-02 (Crawled : 12:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| 13.8% | O: 1.41% H: 0.0% C: -3.13%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| -1.48% | O: -0.61% H: 0.08% C: -0.29%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 5.05% | O: -1.08% H: 1.44% C: 1.28%
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| 13.47% | O: -0.29% H: 1.55% C: 1.2%
CRNX | $42.98 -0.07% -0.07% 620K |

Health Technology

| 144.56% | O: -0.57% H: 5.9% C: 5.44%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 0.31% | O: -0.23% H: 0.79% C: 0.43%
ADAP | $0.97 7.97% 7.38% 1.5M |

Health Technology

| -51.49% | O: -0.99% H: 6.5% C: 3.0%
research report therapy cancer market

---

Global NASH Market to Soar to $2.71 Billion by 2023, Driven by Rising Prevalence of Silent Liver Disease
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
IVA | $3.35 -2.9% -2.99% 8.5K |

Health Technology

| Email alert Add to watchlist
GALT | $3.37 -0.3% -0.3% 210K |

Health Technology

| Email alert Add to watchlist
GNFT | $3.59 4.03% 2.1K |

Health Technology

| Email alert Add to watchlist
ICPT | $19.0 -0.05% 4M |

Health Technology

| Email alert Add to watchlist
IVEVF | $3.73 0% 1K |

n/a

| Email alert Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| Email alert Add to watchlist
NVSEF | $93.6375 6.88% 82K |

Health Technology

| Email alert Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| Email alert Add to watchlist
MDGL | $212.33 -4.47% -4.68% 620K |

Health Technology

| Email alert Add to watchlist
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| Email alert Add to watchlist
GLMD | $0.3787 -0.41% 18K |

Health Technology

| Email alert Add to watchlist
liver disease global nash market

---

Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51% of market growth- Technavio
Published: 2023-10-27 (Crawled : 19:00) - prnewswire.com
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| Email alert Add to watchlist
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| Email alert Add to watchlist
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| Email alert Add to watchlist
IVEVF | $3.73 0% 1K |

n/a

| Email alert Add to watchlist
IVA | $3.35 -2.9% -2.99% 8.5K |

Health Technology

| Email alert Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| Email alert Add to watchlist
america market

---

Global MRSA Drugs Markets, 2017-2022, 2022-2027F, 2032F: Focus on Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, & Lipoglycopeptide
Published: 2023-09-08 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 1.13% | O: 0.86% H: 0.0% C: -0.1%
IPIX | $0.0101 92.86% 230K |

Manufacturing

| -40.48% | O: 0.0% H: 1.19% C: 0.6%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 11.75% | O: 0.07% H: 0.0% C: 0.0%
CPIX | $1.65 6.02% 790 |

Health Technology

| -4.19% | O: -2.99% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 0.81% | O: 0.49% H: 0.24% C: -0.16%
global

---

Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research
Published: 2023-09-01 (Crawled : 14:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 1.61% | O: 1.46% H: 0.0% C: 0.0%
ALPMY | $9.47 -1.11% 520K |

Manufacturing

| -37.25% | O: -0.07% H: 3.3% C: 0.26%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 12.11% | O: -0.35% H: 0.0% C: 0.0%
CPIX | $1.65 6.02% 790 |

Health Technology

| -3.03% | O: 0.61% H: 0.0% C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -27.3% | O: 0.62% H: 0.26% C: -0.68%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 1.08% | O: 0.86% H: 0.16% C: -0.38%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| 4.91% | O: 0.91% H: 0.14% C: -0.76%
research market

---

Global Gynecology Drugs Market Report 2021-2026: Focus on Cancers, Polycystic Ovary Syndrome, Contraception, Endometriosis, Female Infertility, Infections, Postmenopausal Disorders
Published: 2021-08-23 (Crawled : 16:00) - prnewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| -5.02% | O: -0.24% H: 0.19% C: -0.62%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 168.59% | O: 0.7% H: 0.22% C: -1.65%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 40.05% | O: 0.82% H: 0.54% C: -0.37%
ABT | News | $107.28 1.91% 0.18% 10M |

Health Technology

| -14.67% | O: 0.76% H: 0.5% C: -0.66%
TXMD | News | $1.86 -1.59% -1.61% 10K |

Health Technology

| 135.44% | O: -0.51% H: 7.79% C: 4.07%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -12.44% | O: -0.28% H: 0.09% C: -0.59%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 15.42% | O: -0.51% H: 0.44% C: -0.49%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| 19.89% | O: -0.06% H: 1.45% C: 0.65%
cancer drug injection syndros contraceptive infections

---

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio
Published: 2024-01-26 (Crawled : 02:00) - prnewswire.com
XLO | $1.16 -9.38% -10.34% 340K |

Professional, Scientific, and T...

| 79.69% | O: 4.69% H: 4.55% C: -2.99%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 3.15% | O: 2.92% H: 1.06% C: -3.05%
BNTX | $86.82 0.75% 0.75% 1.6M |

Health Technology

| -10.41% | O: -1.35% H: 0.12% C: -0.83%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 2.28% | O: 1.07% H: 0.1% C: -0.94%
AGEN | $5.3 6.64% 6.23% 1.5M |

Health Technology

| 785.3% | O: 3.13% H: 11.02% C: 7.11%
protein growth market

---

Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| -1.6% | O: 3.52% H: 0.0% C: -1.18%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 12.87% | O: 0.06% H: 2.34% C: 2.29%
ALPMY | $9.47 -1.11% 520K |

Manufacturing

| -12.2% | O: 0.37% H: 0.74% C: 0.28%
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -7.48% | O: 0.14% H: 0.35% C: 0.07%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -6.14% | O: -0.34% H: 0.23% C: -1.13%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -5.55% | O: 0.7% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| -3.21% | O: 1.22% H: 0.07% C: -0.43%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| -1.49% | O: -0.96% H: 1.75% C: 1.75%
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -1.65% | O: -0.18% H: 0.48% C: -1.91%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| -3.85% | O: 0.8% H: 0.0% C: 0.0%
ZLAB | $14.08 -0.99% -0.99% 470K |

Health Technology

| -22.73% | O: -1.15% H: 1.03% C: -1.5%
VRTX | News | $394.43 0.24% 0.24% 1.3M |

Health Technology

| -5.79% | O: -0.28% H: 0.49% C: -0.32%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| 0.22% | O: -0.06% H: 0.0% C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K |

Health Technology

| -5.43% | O: -3.1% H: 1.2% C: -0.8%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -9.49% | O: 3.8% H: 1.1% C: -1.17%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -20.58% | O: -3.72% H: 0.58% C: -3.82%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 11.63% | O: -0.26% H: 0.73% C: -0.36%
ARGX | $360.11 0.47% 0.47% 330K |

Health Technology

| -8.27% | O: -2.3% H: 1.65% C: 0.83%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| -8.66% | O: 0.06% H: 0.31% C: -1.4%
expansion growth market

---

Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
Published: 2020-12-23 (Crawled : 18:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| -83.86% | O: 4.37% H: 0.88% C: -8.78%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 40.67% | O: 0.78% H: 0.02% C: -0.69%
license antibody milestone

---

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
Published: 2021-08-19 (Crawled : 11:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| -61.71% | O: -1.67% H: 3.91% C: -1.36%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 15.33% | O: -0.54% H: 1.13% C: 0.12%
antibody

---

Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| -61.64% | O: 0.5% H: 4.17% C: 0.83%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 15.62% | O: 1.28% H: 0.83% C: 0.82%
milestone

---

Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
Published: 2023-02-14 (Crawled : 17:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| 193.59% | O: 3.85% H: 5.86% C: 2.36%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| -1.66% | O: 0.3% H: 0.94% C: 0.6%
com902 antibody expected

---

Compugen Reports Third Quarter 2023 Results
Published: 2023-11-07 (Crawled : 12:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| 216.21% | O: -0.03% H: 0.0% C: -5.83%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 7.03% | O: -0.59% H: 0.46% C: -0.09%
results

---

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2024-01-08 (Crawled : 12:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| 30.86% | O: 2.29% H: 8.38% C: 4.47%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 0.25% | O: 0.28% H: 0.99% C: 0.93%
first million payment astrazeneca cancer trial milestone

---

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2023-12-19 (Crawled : 12:30) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| 213.7% | O: 178.08% H: 21.18% C: -1.48%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 3.94% | O: -0.5% H: 0.99% C: 0.43%
first payment astrazeneca cancer trial milestone

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---